

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 November 2023 (30.11.2023)



(10) International Publication Number
WO 2023/227505 A1

(51) International Patent Classification:

A61K 9/08 (2006.01) *A61K 47/26* (2006.01)
A61K 38/00 (2006.01) *A61K 47/50* (2017.01)
A61K 47/12 (2006.01) *A61K 47/60* (2017.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2023/063596

(22) International Filing Date:

22 May 2023 (22.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22174758.7 23 May 2022 (23.05.2022) EP

(71) Applicant: **ASCENDIS PHARMA GROWTH DISORDERS A/S** [DK/DK]; Tuborg Boulevard 12, 2900 Hellerup (DK).

(72) Inventors: **HERSEL, Ulrich**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). **WOODS, Tom**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 96120 Heidelberg (DE). **LADIGES, Andrea**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). **SCHRÖDER, Steffen**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE).

(74) Agent: **BÜCHEL, Edwin**; Patentanwälte Isenbruck Bösl Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS

(57) Abstract: A liquid pharmaceutical formulation comprising a CNP compound, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and methods for making and using such formulation.

WO 2023/227505 A1